The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
Accelerated upstream process development of adeno-associated viruses from high‐throughput systems to clinical scale
Reduce cost, improve yield, and scale AAV manufacturing with optimized upstream development strategies.
Scaling AAV manufacturing remains a major bottleneck—driving high costs, long timelines, and inconsistent product quality. At Thermo Fisher Scientific, our team of dedicate experts work around the clock to strategize and implement innovative processes to alleviate these bottlenecks.
Download this case study to see how optimized upstream process development and seamless scale-up can significantly reduce Cost of Goods (COGs) while accelerating timelines to clinical and commercial production.
Key takeaways:
- Reduce cost and improve yield: Learn how optimizing transfection conditions can lower cost of goods by up to ~60% while maintaining strong productivity and quality.
- De-risk scale-up: See how processes developed in high-throughput systems can reliably translate to 2,000 L scale without compromising titer or capsid quality.
- Accelerate development timelines: Discover strategies to move from process development to clinical-scale manufacturing in months—not years—through smarter DoE and engineering controls.
Additional resources
Webinar
Revolutionizing gene therapy manufacturing: Robotics and machine learning for process intensification
This on-demand webinar highlights the benefits of leveraging machine learning, high-throughput process and analytical development, and perfusion intensification for viral vector production.
Blog post
Advancing viral vector development through Quality by Design approach
Explore more on NysnoBio's partnership with Thermo Fisher, focusing on a quality by design approach to viral vector development and manufacturing.